Why PCVX rose 18.6% on Oct 5 2026: phase 3 trial success
PCVX+18.6%on Mon Oct 5 2026
Vaxcyte, Inc. Common Stock was up 18.6% on the day at $67.00, ranked #2 on 3.3× its usual five-minute volume, when TapeRank recorded this unexplained move at 06:04 ET during the pre-market session. TapeRank recorded 2 events for PCVX that day, between 06:04 and 06:06 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 06:04 ETUNEXPLAINED MOVE · PRE-MARKET
$67.00 · ▲ 18.6% ON THE DAY · 3.3× 5M RVOL · RANK #2
JUSTIFIEDCONFIDENCE5/5PCVX is up 25.7% pre-market, with a 13.93% surge in the last five minutes. The move follows positive topline Phase 3 VAX-31 results meeting all prespecified primary endpoints, including superiority for unique serotypes and a comparable safety profile.
WHYA 25.7% move is large, but is proportionate to a pivotal Phase 3 vaccine trial meeting all primary endpoints and supporting a planned BLA.ANALYZED 06:07 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 06:04 ET
LAST67.00DAY▲ 18.6%5 MIN▲ 5.18%5M RVOL3.3×5M $VOL$215KFLOAT*148.8MRANK#2SESSIONPRE-MARKETVWAP60.91HOD63.70LOD58.75OR HIGH—OR LOW—PREV CLOSE56.48PM HIGH63.70PM LOW58.75GAP▲ 10.34% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 06:06 ETMOVER · PRE-MARKET
$72.00 · ▲ 27.5% ON THE DAY · 11.5× 5M RVOL · RANK #2
The same verdict as at 06:04 ET.
THE ROW AND SESSION LEVELS AT 06:06 ET
LAST72.00DAY▲ 27.5%5 MIN▲ 15.53%5M RVOL11.5×5M $VOL$696KFLOAT*148.8MRANK#2SESSIONPRE-MARKETVWAP62.57HOD71.30LOD58.75OR HIGH—OR LOW—PREV CLOSE56.48PM HIGH71.30PM LOW58.75GAP▲ 26.24% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $87.21, +54.4% on the previous close of $56.48
- 09:34 ETRegular-session high, $90.75
- 12:44 ETRegular-session low, $71.60
- 15:59 ETLast trade of the regular session, $73.96, +30.9% on the previous close of $56.48
- Volume: 11.8M shares in regular hours, 2.3M before the open
PCVX was already moving before the open, rising from $67.00 at 06:04 ET to $72.00 two minutes later after positive topline Phase 3 VAX-31 results met all prespecified primary endpoints, including superiority for unique serotypes and a comparable safety profile. TapeRank read the move as justified by the phase 3 trial success and its support for a planned BLA; no filing or news was found in the prior 24 hours. The stock opened at $87.21, reached $90.75 at 09:34 ET, then fell to $71.60 at 12:44 ET before ending at $73.96, with no halts.
WRITTEN THU OCT 15 2026 18:01 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
No SEC filings or wire news in the 24 hours before this was recorded. A move on news that never reached the wire shows nothing here, which is what UNEXPLAINED means.
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list